Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
The study is conducted in Europe. The aim of this observational study is to assess glycaemic control while using liraglutide under normal clinical practice conditions in Belgium.
Interventions
DRUGliraglutide
Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes * Insufficiently controlled after 3 months of treatment with OADs (oral anti-diabetic drugs)
Exclusion criteria
* Previously treated with liraglutide * Hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections) * Pregnant, breast feeding or have the intention of becoming pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1% | month 12 |
| Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1% | month 12 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of serious adverse events (SAEs) | months 0-12 |
| HbA1c | month 12 |
| Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar) | months 0-12 |
| Incidence of adverse drug reactions (ADRs) | months 0-12 |
| Fasting blood glucose (FBG) | month 12 |
Countries
Belgium
Outcome results
None listed